Mepivacaine Accord (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is essential for depolarisation. By inhibiting impulse propagation, it temporarily stops the transmission of pain signals from the site of administration to the central nervous system.

The appropriate dose of Mepivacaine Accord is determined by the prescribing clinician based on the type of procedure, patient weight, age, comorbidities and the specific route of administration. Only a qualified healthcare professional should set the dosing regimen.

Safety data for mepivacaine in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful assessment.

To request Mepivacaine Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mepivacaine is an amide‑type local anesthetic with a rapid onset and intermediate duration of action. Compared with lidocaine, it has a slightly longer duration and less vasodilatory effect, which can reduce the need for a vasoconstrictor in certain procedures.

Mepivacaine Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperature fluctuations to maintain its stability and sterility.

The solution is administered by a qualified healthcare professional via epidural, infiltration or perineural injection techniques. Proper aseptic technique, aspiration before injection and careful monitoring of the patient are essential components of safe administration.

Serious risks include central nervous system toxicity such as seizures, cardiovascular events like arrhythmias or severe hypotension, and rare allergic reactions that may progress to anaphylaxis. Immediate medical attention is required if any of these symptoms occur.

Patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics, those with significant cardiac conduction disorders, severe liver disease, or those taking interacting Class I antiarrhythmics should avoid Mepivacaine Accord unless a specialist determines that benefits outweigh risks.